top of page
Our
Platforms
MiniBinders: A novel approach to extracellular protein degradation
-
We have identified a novel modality that is well-suited for targeted protein degradation.
-
We have identified and characterized E3 ligases expressed on cancer cells, opening up the door to new targets and indications.

CargoTek: Re-doseable AAV therapies
-
Demonstrated re-dosing of AAV in mice with CargoTek.
-
Entered into a strategic research collaboration with AAV company.

StressTek: rHSPB5 treatment for autoimmune disorders
-
Unconventional use of rHSPB5 as a therapeutic.
-
Acquired rights to DC-TAB, previously in the clinic for MS, in 2020.
-
Demonstrated POC studies in 2021-2022.

bottom of page